Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Relay Therapeutics ( (RLAY) ) has issued an update.
On April 27, 2026, Relay Therapeutics reported Phase 1/2 ReDiscover data for its triplet regimen of zovegalisib, atirmociclib and fulvestrant in heavily pre-treated, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The combination showed a 44% objective response rate across kinase and non-kinase PIK3CA mutations, 85% tumor reduction in evaluable patients, and manageable safety with low discontinuation rates and no grade 3 hyperglycemia despite a high proportion of pre-diabetic patients.
The company also outlined plans to advance zovegalisib plus atirmociclib into a randomized Phase 3 frontline trial with an aromatase inhibitor in endocrine sensitive PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer, targeting progression-free survival as the primary endpoint. Under a clinical trial supply agreement, Pfizer will provide atirmociclib for the experimental arm and palbociclib for part of the control arm, while Relay will sponsor and fund the study, reinforcing its bid to position zovegalisib-based regimens as potential best-in-class options in the competitive breast cancer market.
The most recent analyst rating on (RLAY) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
Overall score reflects strong recent price momentum and positive clinical/regulatory developments (Breakthrough Therapy designation and supportive trial data), offset by weak fundamentals—persistent losses, negative free cash flow, and ongoing cash burn—plus limited support from traditional valuation metrics due to negative earnings and no dividend.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
Relay Therapeutics, Inc., based in Cambridge, Mass., is a clinical-stage small molecule precision medicine company focused on developing targeted therapies for cancer and genetic diseases. Built around its Dynamo platform, the company’s lead asset is zovegalisib, a first-in-class pan-mutant selective PI3Kα inhibitor in Phase 3 development for HR+/HER2- metastatic breast cancer and under investigation for PI3Kα-driven vascular anomalies.
Average Trading Volume: 2,803,677
Technical Sentiment Signal: Buy
Current Market Cap: $2.86B
For detailed information about RLAY stock, go to TipRanks’ Stock Analysis page.